BioStem Technologies has filed a notice of an exempt offering of securities to raise $40 Million in New Funding.
According to filings with the U.S. Securities and Exchange Commission, BioStem Technologies is raising up to $40,000,000.00 in new funding. The federal securities law requires the notice to be filed...
According to filings with the U.S. Securities and Exchange Commission, BioStem Technologies is raising up to $40,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About BioStem Technologies
BioStem Technologies develops and provides tissue-based solutions for clinicians in surgical and wound care settings. Its product portfolio includes advanced perinatal tissue allografts designed to retain natural structural and molecular factors and support recovery when used as barrier membranes. The companys products are marketed as structural tissue allografts for homologous use, serving as barriers, wound coverings, conduits, and cushions in patient treatment. BioStem reports more than 40 years of research and development, over 1.2 million human clinical applications, and more than 400 peer-reviewed publications. The company is also expanding its portfolio of perinatal allograft technologies for surgical applications and offers sales support, clinical data, and reimbursement resources to medical practices. BioStem additionally supports the Florida Panthers Heroes Among Us and Seats for Service programs, recognizing and rewarding active and veteran military members.
To learn more, visit https://biostemtechnologies.com/
LinkedIn: https://www.linkedin.com/company/biostem-technologies/
Contact:
Jason Matuszewski, Chief Executive Officer
https://www.linkedin.com/in/jason-matuszewski-034163b4/
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.



No Comment! Be the first one.